This Kalorama Information market research report, Pharmaceutical Products of the Future: 50-Company Pipeline Analysis to 2015 captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines) and providing estimates and forecasts of the world biopharma market.
Among the top companies in biopharmaceuticals are, not surprisingly, the same names that have dominated pharmaceuticals for years – Pfizer, Merck and Novartis. These companies have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts. Specialist companies such as Amgen and Genzyme, now competing with a growing number of companies. The result of all interest in biological solutions to major diseases? In creased activity in the research and development departments of major pharmaceutical companies in recent years, activity that we believe will have near-term market impact.
- Biotechnology Drug Development
- Orphan Drugs
- Fast Track Drug Status
- Other Accelerated Methods for Drug Approval
- Pharmaceutical Regulatory Exclusivity
- Biosimilar Development
- Aging Populations
- Mergers, Acquisitions, and Collaborations
- Contributors to R&D Success
- R&D Spending Trends
- The Role of Contract Research Organizations
- Sustainability in a Changing Pharmaceutical Industry
Also, despite an in-depth interview process and complete review of company financials, some variation in company rankings is possible. This is more likely with privately held companies or companies where prescription pharmaceutical and biopharmaceutical sales are not discussed.
In this comprehensive look a the pipeline of major companies, Kalorama Information presents an accurate picture of the marketplace today, including
- Market Estimates by Major Drug Category, including:
- Discussion of Marketplace Trends
- Pipeline Analysis of Major Pharmacos
- Detailed Company Profiles
- Comparison of Market at Current Growth Versus Impact of Late-Stage Products
- Biopharmaceutical Market Breakdown
- Best-Selling Biopharmaceutical Products
- Regulatory Activity and Market Impact
Kalorama Information’s market research into this topic is based on review of government filings and company literature, but also interviews with executives and experts, and the perspective of an analyst who has authored scores of reports in this industry.
50 top companies make up over 90% of the world biopharmaceutical market; The top three companies have nearly a quarter of global sales in 2009.
Late Stage Product Development of the Top 50 Companies
Kalorama looks at each key player’s late-stage pipeline in detail. The top 50 companies discussed in this report include:
- Alcon, Inc.
- Baxter International
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene Corp.
- Chugai Pharmaceutical
- Daiichi Sankyo
- Eli Lilly & Co.
- Gilead Sciences
- Johnson & Johnson
- Merck KGaA
- Mitsubishi Tanabe Pharma
- Novo Nordisk
- Ono Pharmaceutical Co.
- Otsuka Pharmaceutical
- Procter & Gamble
- Purdue Pharma